ATE489108T1 - Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie - Google Patents

Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie

Info

Publication number
ATE489108T1
ATE489108T1 AT99956525T AT99956525T ATE489108T1 AT E489108 T1 ATE489108 T1 AT E489108T1 AT 99956525 T AT99956525 T AT 99956525T AT 99956525 T AT99956525 T AT 99956525T AT E489108 T1 ATE489108 T1 AT E489108T1
Authority
AT
Austria
Prior art keywords
tumor
flt4
vegfr
imaging
target
Prior art date
Application number
AT99956525T
Other languages
German (de)
English (en)
Inventor
Kari Alitalo
Arja Kaipainen
Reija Valltola
Lotta Jussila
Original Assignee
Vegenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/169,079 external-priority patent/US6824777B1/en
Application filed by Vegenics Ltd filed Critical Vegenics Ltd
Application granted granted Critical
Publication of ATE489108T1 publication Critical patent/ATE489108T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99956525T 1998-10-09 1999-10-08 Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie ATE489108T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/169,079 US6824777B1 (en) 1992-10-09 1998-10-09 Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
PCT/US1999/023525 WO2000021560A1 (en) 1998-10-09 1999-10-08 Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY

Publications (1)

Publication Number Publication Date
ATE489108T1 true ATE489108T1 (de) 2010-12-15

Family

ID=22614189

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99956525T ATE489108T1 (de) 1998-10-09 1999-10-08 Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie

Country Status (13)

Country Link
US (4) US8444957B2 (es)
EP (1) EP1119371B1 (es)
JP (5) JP4841724B2 (es)
CN (1) CN100340291C (es)
AT (1) ATE489108T1 (es)
AU (2) AU774266B2 (es)
CA (1) CA2345276C (es)
DE (1) DE69942981D1 (es)
DK (1) DK1119371T3 (es)
ES (1) ES2357406T3 (es)
NO (1) NO20011759L (es)
NZ (2) NZ529063A (es)
WO (1) WO2000021560A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
EP1382679A3 (en) 1995-09-08 2004-11-10 Genentech, Inc. Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
DK1119371T3 (da) * 1998-10-09 2011-03-07 Vegenics Ltd Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP1553414A1 (en) * 1999-04-13 2005-07-13 Medarex, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
US6965010B2 (en) 2000-02-25 2005-11-15 Licentia, Ltd. Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
KR20020059609A (ko) 2000-08-04 2002-07-13 벤슨 로버트 에이치. 혈관 내피 성장 인자 ２
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
JP4669984B2 (ja) * 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
EP1385864B1 (en) 2001-04-13 2010-06-09 Human Genome Sciences, Inc. Anti-VEGF-2 antibodies
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2452058A1 (en) * 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2005049852A2 (en) * 2003-11-17 2005-06-02 University Of Florida Methods and compositions for inducing apoptosis
JP2007523649A (ja) 2004-02-10 2007-08-23 サーナ・セラピューティクス・インコーポレイテッド 多機能短鎖干渉核酸（多機能ｓｉＮＡ）を用い、ＲＮＡ干渉を介した遺伝子発現の阻害
WO2005087177A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1919944B1 (en) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modified vegf and pdgf with improved angiogenic properties
US7629125B2 (en) 2006-11-16 2009-12-08 General Electric Company Sequential analysis of biological samples
US8305579B2 (en) 2006-11-16 2012-11-06 Thomas Pirrie Treynor Sequential analysis of biological samples
US9201063B2 (en) 2006-11-16 2015-12-01 General Electric Company Sequential analysis of biological samples
US9677125B2 (en) 2009-10-21 2017-06-13 General Electric Company Detection of plurality of targets in biological samples
US9328162B2 (en) 2010-02-25 2016-05-03 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2014064203A1 (en) 2012-10-26 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
HUE048687T2 (hu) 2013-02-18 2020-08-28 Vegenics Pty Ltd Ligandum kötõ molekulák és alkalmazásaik
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
KR102131370B1 (ko) 2013-10-18 2020-07-08 삼성전자주식회사 Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
IL74201A0 (en) 1984-01-30 1985-04-30 Icrf Patents Limited Polypeptides for the detection and control of mammalian cell growth
ES2006109A6 (es) 1987-03-11 1989-04-01 Erba Carlo Spa Un procedimiento para preparar un conjugado de inmunoglobulina.
EP1762623A1 (en) 1988-01-22 2007-03-14 ZymoGenetics, Inc. Methods for producing biologically active peptide dimers
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2011450C (en) 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
WO1990014425A1 (en) 1989-05-22 1990-11-29 Zymogenetics, Inc. PDGF α-RECEPTOR
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0584082B1 (en) 1991-01-31 2000-05-31 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5256766A (en) 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
DE69232718T2 (de) 1991-02-22 2003-04-03 American Cyanamid Co Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
US5231001A (en) 1991-03-14 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
US5270458A (en) 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
EP0620826A1 (en) 1992-01-09 1994-10-26 Helsinki University Holding, Ltd. Tie, a novel endothelial cell receptor tyrosine kinase
JPH07504813A (ja) 1992-01-22 1995-06-01 ニユー・イングランド・デイーコネス・ホスピタル 新規蛋白質チロシンキナーゼ類
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5776755A (en) 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
EP1975181B1 (en) 1992-10-28 2011-02-16 Genentech, Inc. Use of vascular endothelial cell growth factor antagonists
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
CA2184584C (en) 1994-03-08 2003-04-08 Jing-Shan Hu Vascular endothelial growth factor 2
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
ATE326484T1 (de) * 1994-06-09 2006-06-15 Licensing Oy Monoklonaler antikörper gegen flt4-rezeptor- tyrosinkinase und dessen verwendung zur diagnose und therapie
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
WO1998033917A1 (en) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
EP1382679A3 (en) 1995-09-08 2004-11-10 Genentech, Inc. Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
ES2327440T3 (es) 1996-08-23 2009-10-29 Vegenics Limited Factor recombinante de crecimiento de las celulas endoteliales vasculares-d (vegf-d).
EP1054687B8 (en) 1997-12-24 2008-07-16 Vegenics Limited Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
DK1119371T3 (da) * 1998-10-09 2011-03-07 Vegenics Ltd Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
KR101681886B1 (ko) 2015-04-06 2016-12-12 서울대학교산학협력단 지르코니아 결합능을 가지는 펩타이드

Also Published As

Publication number Publication date
JP4841724B2 (ja) 2011-12-21
US8444957B2 (en) 2013-05-21
NZ511408A (en) 2004-04-30
JP2015157829A (ja) 2015-09-03
WO2000021560A9 (en) 2000-09-21
JP2002527404A (ja) 2002-08-27
NO20011759L (no) 2001-06-11
JP2011121957A (ja) 2011-06-23
AU2004208675A1 (en) 2004-09-30
WO2000021560A1 (en) 2000-04-20
US20100278736A1 (en) 2010-11-04
DE69942981D1 (de) 2011-01-05
AU1312100A (en) 2000-05-01
JP2013209382A (ja) 2013-10-10
US20150158928A1 (en) 2015-06-11
DK1119371T3 (da) 2011-03-07
CN1329504A (zh) 2002-01-02
US20140072511A1 (en) 2014-03-13
CN100340291C (zh) 2007-10-03
JP2012019790A (ja) 2012-02-02
JP5784310B2 (ja) 2015-09-24
CA2345276A1 (en) 2000-04-20
US20160184405A1 (en) 2016-06-30
NZ529063A (en) 2005-07-29
ES2357406T3 (es) 2011-04-26
EP1119371A1 (en) 2001-08-01
NO20011759D0 (no) 2001-04-06
AU774266B2 (en) 2004-06-24
CA2345276C (en) 2011-03-29
JP5642637B2 (ja) 2014-12-17
EP1119371B1 (en) 2010-11-24
AU2004208675B2 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
ATE489108T1 (de) Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
NO20033285D0 (no) FLT4(VEGFR-3) som et mål for tumoravbildning og anti-tumor terapi
PT842273E (pt) Ligando de receptor vegf-c
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
CY1112101T1 (el) Νευροτροφικοι παραγοντες
CY1107339T1 (el) Mu-1, μελος της οικογενειας υποδοχεα κυτοκινης
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO1999033870A3 (en) Human regulatory proteins
GB9811260D0 (en) Novel compounds
CY1105820T1 (el) Basb027 πρωτεϊνες και γονιδια απο moraxella catarrhalis, αντιγονα, αντισωματα και χρησεις
EP0821060A3 (de) E-Cadherin-Mutationen als Grundlage zur Diagnostik und Therapie humaner maligner Tumoren
GB9820003D0 (en) Novel compounds
WO2000023589A3 (en) Proliferation and apoptosis related proteins
GB9809683D0 (en) Novel compounds
GB9812163D0 (en) Novel compounds
GB9810285D0 (en) Novel compounds
TR200102745T2 (tr) Yeni bileşikler
GB9812440D0 (en) Novel compounds
ATE481486T1 (de) Gbs toxin rezeptor
GB9918208D0 (en) Novel compounds
WO2003016479A3 (en) Excitatory glycine receptors and methods
AU2002360392A8 (en) New gene expressed in prostate cancer and methods of use
GB0025170D0 (en) Novel compounds
GB9918003D0 (en) Novel compounds
GB9918302D0 (en) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1119371

Country of ref document: EP